05:58 PM EDT, 05/07/2025 (MT Newswires) -- ADMA Biologics ( ADMA ) reported Q1 earnings late Wednesday of $0.11 per diluted share, up from $0.08 a year earlier.

Three analysts polled by FactSet expected $0.15.

Revenue in the three months ended March 31 rose to $114.8 million from $81.9 million a year earlier. Three analysts surveyed by FactSet expected $116.4 million.

The company raised 2025 revenue guidance to over $500 million from over $490 million and boosted the 2026 forecast to over $625 million from $605 million.

Three analysts expect $496.1 million this year and $629.7 million in 2026.

The board authorized a stock repurchase program of up to $500 million

The company's shares fell 4.7% in after-hours trading.